Mendelian Randomization Reveals Potential Drug Targets for Multiple Sclerosis Targeting Ferroptosis

Area of Science:

• Genetics
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a complex autoimmune disease with limited treatment options for disease progression.
• Ferroptosis, a regulated cell death pathway, has been implicated in MS pathogenesis.
• Identifying novel therapeutic targets is crucial for improving MS management.

Purpose of the Study:

• To investigate the role of ferroptosis-related proteins in MS using a Mendelian randomization approach.
• To identify potential therapeutic targets for MS by analyzing genetic associations with ferroptosis pathways.
• To explore the link between ferroptosis-related proteins and existing MS therapeutics.

Main Methods:

• Mendelian randomization analysis using genetic data from GTEx v8, deCODE, and the International MS Genetics Consortium.
• Analysis of transcription and proteomic data for 511 ferroptosis-related proteins across 49 tissues.
• Application of techniques including reverse Mendelian randomization, Bayesian colocalization, and phenomewide scanning.
• Exploration of protein-protein interaction networks to identify links with approved MS drugs.

Main Results:

• Nine ferroptosis-related proteins, including STAT3, MAPK1, MAPK3, and ZEB1, showed significant associations with MS risk.
• Four proteins (STAT3, MAPK1, MAPK3, ZEB1) demonstrated shared genetic variation with MS.
• STAT3 and MAPK3 were identified as potential therapeutic targets, with STAT3 showing a strong association and interaction with current MS drug targets.
• Protein-protein interaction analysis revealed connections between STAT3 and MAPK3 with targets of existing MS medications.

Conclusions:

• Ferroptosis pathways causally contribute to MS pathogenesis.
• STAT3 and MAPK3 are highlighted as promising therapeutic candidates for MS.
• This research offers new insights into MS biology and directs future drug development towards ferroptosis regulation.